You are here: Industry Insights > Amgen

News List

Amgen begins rolling out Humira biosimilar in the EU pharmatimes
October 19, 2018
Amgen has begun launching Amgevita, the first biosimilar of AbbVie’s anti-inflammatory blockbuster Humira to win approval in Europe, across the region.
Amgen, Novartis first to launch Humira biosimilars in Europe biospectrumasia
October 17, 2018
Tags: Top Story Amgevita Humira Hyrimoz AbbVie Amgen Novartis Arthritis IBD Psoriasis General Practice Internal Medicine Marketing & Sales
Amgen leaves celeb spokeswoman Blythe Danner behind in newest Prolia ad fiercepharma
September 21, 2018
Amgen osteoporosis drug Prolia is working to appeal to menopausal women with a new TV ad, but it's leaving behind celebrity spokeswoman actress Blythe Danner.
Amgen, Los Angeles County Announce Collaboration americanpharmaceuticalreview
September 21, 2018
Amgen and the County of Los Angeles announced that Amgen has agreed to become a founding sponsor of BioLA, a newly formed organization focused on advancing a life science innovation hub in Los Angeles County.
Mylan biosimilar to stress test Amgen Neulasta franchise, analyst predicts biopharmadive
September 20, 2018
The importance of Mylan's copycat extends well beyond the bottom lines of the two drugmakers directly involved. Leerink analyst Geoffrey Porges called it "the latest battle" in the space that "will set the industry tone for biosimilar adoption in the near
AstraZeneca and Amgen receive breakthrough status for tezepelumab September 11, 2018
AstraZeneca and Amgen have received breakthrough therapy designation for tezepelumab to treat severe asthma, irrespective of an eosinophilic phenotype.
Amgen’s Blincyto gets EU approval for relapsed B cell precursor ALL pharmaceutical-technology
September 04, 2018
On June 19, Amgen announced that the European Commission (EC) has granted full approval for the bispecific antibody drug, Blincyto (blinatumomab), for patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymph
Amgen Submits Supplemental New Drug Application for Kyprolis americanpharmaceuticalreview
August 28, 2018
Amgen announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the Prescribing Information for Kyprolis (carfilzomib) to include a once-weekly dosing option in combination with dexamet
Amgen's quick Aimovig launch boosts blockbuster hopes for Lilly, Teva and Alder: analyst fiercepharma
August 21, 2018
Amgen's migraine prevention drug Aimovig, just approved in May, is riding a rising wave of early demand—and that's a good thing, not just for Amgen and its partner Novartis, but for other forthcoming drugs in the CGRP class, an analyst said Monday.
Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island worldpharmanews
August 06, 2018
Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich......

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page